tiprankstipranks
Blurbs

Stifel Nicolaus Sticks to Their Buy Rating for Rapid Micro Biosystems (RPID)

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Rapid Micro Biosystems (RPIDResearch Report) on August 16 and set a price target of $9.00. The company’s shares closed yesterday at $3.56.

According to TipRanks, Arias is a 3-star analyst with an average return of 4.0% and a 56.56% success rate. Arias covers the Healthcare sector, focusing on stocks such as Illumina, PerkinElmer, and Agilent.

Rapid Micro Biosystems has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.

See the top stocks recommended by analysts >>

RPID market cap is currently $149.3M and has a P/E ratio of -2.19.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RPID in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company’s flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.

Read More on RPID:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles